Latest News

Analyst Report: Danaher Corp.

0

Danaher Corporation (DHR) Stock Forecasts

AllAnalyst Report

Argus•February 14, 2024

Symbols

DHR

Sector(s)

Healthcare

Rating

Current Price

$247.99

Price Target

Earnings Estimate

Summary

Danaher is a diversified life sciences and diagnostics company with global operations. In March 2020, it acquired the GE Biopharma business and renamed it Cytiva. Danaher has continued to make acquisitions, including Aldevron in 2021 and the pending acquisition of Abcam, that strengthen its technology and manufacturing capabilities.

Subscribe to Yahoo Finance Plus Essential for full access

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level

Actions

Download Full Report

Analyst Profile

David H. Toung

Senior Analyst: Medical Devices & Healthcare Services

David covers the Pharmaceutical, Medical Devices, and Healthcare services sectors for Argus. He has more than two decades of experience in the financial analysis industry, having worked for McDonald & Co., JPMorgan Chase and Standard & Poor’s, among others. His commentary has appeared on CNBC and in The New York Times. Prior to his financial career, David was a private practice attorney in New Jersey, and served as a Judicial Clerk for an Appellate Division judge in the New Jersey Superior Court. David has a law degree from Rutgers University, where he was a member of the Law Review. He has a B.A. degree in Government from Cornell University. He has passed Level II of the Chartered Financial Analyst examination.

Bitcoin regains $1 trillion market cap after a tumultuous two years for crypto

Previous article

Oil falls by $1/bbl as US crude build trumps upbeat demand forecast

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News